Jacob W. Stahl is counsel in the firm’s New York office and a member of the firm’s Litigation Department. His practice focuses on representing clients on healthcare-related issues, including commercial litigation, the False Claims Act, administrative disputes and compliance and regulatory advice. He also represents clients in the areas of class action defense (including actions brought under consumer protection statutes such as the TCPA and FDCPA), mass tort, products liability, general commercial litigation and white collar criminal defense. Mr. Stahl is recommended by Who’s Who Legal: Global Healthcare (2021) as “a formidable litigator who showcases significant expertise when handling administrative disputes in the healthcare sector.”

Mr. Stahl received an LL.M. in Global Health Law from Georgetown University Law Center in 2018, Dean’s List, with Distinction, Thomas Bradbury Chetwood, S.J. Prize, and a J.D. cum laude from Harvard Law School in 2005. He received a B.A. summa cum laude, Phi Beta Kappa from the University of Pennsylvania, in 2001. Mr. Stahl joined the firm in 2005.

Mr. Stahl is the co-author of numerous articles, including “The death of Chevron: Implications of the Loper decision for public companies,” Westlaw Today (September, 2024); “After Chevron: FDA Regulations In The Crosshairs,” Law360 (July, 2024); “What Banks Should Know About TCPA Exam Policy Updates,” Law360 (December, 2023); “Lessons From Federal Fraud Charges Against UBiome,” Law360 (April, 2021); “TCPA Litigation And Compliance After Facebook Ruling,” Law360 (April, 2021); “The American Rescue Plan Act of 2021: Pharmaceutical Industry Impact,” Pharm Exec (March, 2021); “Trump's Drug Pricing Order Is More Bark Than Bite,” Law360 (September, 2020); “Providers, Investors Need Clear Post-Covid Telehealth Picture,” Bloomberg Law (September, 2020); “The SEC/FDA Nexus: Best Practices for Publicly Traded Life Sciences Companies,” Bloomberg Law (November, 2018); “D.C. Circuit Court Decision May Help Level the Playing Field for TCPA Defendants,” Bloomberg BNA (April, 2018); “A Look at Recent Efforts to Contain Health Care Costs,” Law360 (January, 2018); “How Tax Reform Could Impact the Health Care Industry,” Law360 (November, 2017); “How Section 1332 Waivers Could Impact Health Care Reform,” Law360 (July, 2017); “Health Care Winners And Losers From The Better Care Act,” Law360 (June, 2017); “Shining A Light On GOP Plan For Health Care Reform,” Law360 (March, 2017); “The Outlook For The Pharmaceutical Industry Under Trump,” Law360 (January, 2017); “The Outlook On Drug Pricing: At What Cost?,” Law360 (December, 2016); “A Walk in the Park Shouldn’t Lead to Jail Time: Recent Decisions Explain Why Incarceration Is Never Appropriate for ‘Responsible Corporate Officers’ Who Lack Criminal Intent,” Bloomberg BNA Pharmaceutical Law & Industry Report (October, 2016); “FDA’s New Guidance On Cybersecurity For Medical Devices: Important Lessons For The Entire Healthcare Industry,” Bloomberg BNA Health IT Law & Industry Report (April, 2016); “Canada Vs. US Product Liability: Recent Developments,” Law360 (January, 2016); “Avoiding And Defeating Securities Fraud Actions Against Clinical-Stage Biopharmaceutical Companies,” Bloomberg BNA Life Sciences Law & Industry Report (July, 2015); “Food For Thought: Corporate Executives On Notice That DOJ Will Seek To Hold Them Criminally Liable for Contaminated Food Outbreaks And Product Failures,” Bloomberg BNA’s White Collar Crime Report (November, 2014); “It’s A Hard-Knock Life: The Rough-And-Tumble Fight Over Orphan Drug Pricing,” Bloomberg BNA’s Pharmaceutical Law & Industry Report (November, 2014); “DOJ Proposal Shows Focus on Individuals in Corporate Crime,” Law360 (September, 2014); “Compliance Corner: The Clock Is Ticking: 60-Day Rule and FCA Liability for Overpayments,” Bloomberg BNA’s Health Care Fraud Report (September, 2014); “Vicarious Criminal Liability in the Executive Suite for Problems on the Manufacturing Floor,” Bloomberg BNA’s Pharmaceutical Law & Industry Report (April, 2014); and “Enforcement without Guidance: The FDA’s Policing of Online Pharmaceutical Advertisements and Communications,” Bloomberg BNA Pharmaceutical Law & Industry Report (December, 2013).